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Aim: To develop a screening in order to determine 
the more common syndromic and non-syndromic genetic 
SNHL, considering epidemiological data, information and 
the development of new technologies; clinical implications 
and bioethical issues. Materials and Methods: We reviewed 
the literature in order to develop a screening that includes: 
history, patterns of inheritance, physical evaluation, laboratory 
tests, image studies, multidisciplinary approaches and genetic 
tests. Conclusion: The epidemiologic data estimates that 
at least 50% of prelingual HL can be determined by genetic 
alterations. Medical and family histories are extremely 
important to help one achieve a genetic-based SNHL 
diagnosis, and help determine inheritance patterns. Through 
a high suspicion index, syndromic cases can be diagnosed or 
excluded, with a careful evaluation and molecular basis tests 
used to better determine the hearing loss. Genetic tests and 
mitochondrial inheritance should be considered in any family 
with many affected individuals, except when the hearing loss 
was clearly transmitted by a male. In cases of non-syndromic 
SNHL, GJB2 mutation analysis must be proposed.
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INTRODUCTION
Hearing loss (HL) is the most common sensorial 
disorder1, and Sensorineural Hearing Loss (SNHL) affects 
approximately 1 to 3 for 1000 newborn babies2. It is esti-
mated that at least 50% of pre-speech stage hearing loss 
are caused by genetic alterations3; however, we lack ac-
curate epidemiological data about post-speech hereditary 
hearing loss1.
Hereditary cases are further broken down into 
syndromic and non-syndromic. Of pre-speech hearing 
losses, 70% are non-syndromic and the remaining 30% are 
characterized by the presence of other signs and symptoms 
(syndromic)1. Among non-syndromic hearing losses, 80% 
are recessive autosomal (DFNB), 15 to 20% are dominant 
autosomal (DFNA) and less than 2% are X-linked (DFN) 
or mitochondria linked2,3 (Figure 1).
common genetic SNHL, considering epidemiological data, 
information and the development of new technologies, 
clinical implications and bioethical issues.
MATERIALS AND METHODS
We carried out a careful revision, using the follo-
wing keywords: hearing loss, sensorineural hearing loss, 
genetics and diagnosis, in order to draw the investigation 
and approach road map. 
LITERATURE REVIEW
Genetic SNHL may follow a dominant autosomal 
pattern, recessive autosomal, X-linked or mitochondria-
linked (Figures 2 and 3). The genetic basis is highly com-
plex. Allelic mutations in some genes can cause recessive 
and dominant HL, mutations in this gene can cause syn-
dromic and non-syndromic HL and, recessive HL can be 
caused by a combination of two mutations in different 
genes of the same functional group3,5.
Figure 1. Pre-speech SNHL: epidemiological data from developed 
countries - this breaking down of hearing loss based on cause (colu-
mn 1), presence or absence of associated traces in cases of genetic 
etiology (column 2) and the inheritance mode in the non-syndromic 
group (column 3). In column 3, box 1 represents X-linked hearing 
loss (approximately 1% of the non-syndromic) and box 2 represents 
mitochondrial hearing loss, which explains at least 1%.  AR: recessive 
autosomal; AD: dominant autosomal. (Modified from Schrijver, 2004)
The syndromic hearing loss is characterized by 
additional manifestations such as: retinitis pigmentosa 
(Usher’s Syndrome), euthyroidism goiter and inner ear 
malformations (Pendred’s Syndrome), renal anomalies 
(Alport’s Syndrome) and presence of enlarged QT interval 
(Jervell’s and Lange-Nielsen’s Syndromes). Associated signs 
and symptoms are useful when they can be observed; 
however they can appear later on, or not be recognized 
at all, thus making the diagnosis incomplete4.
OBJECTIVE
We propose a road map to investigate the most 
Figure 2. Inheritance mode - the first key represents the inheritance of 
a dominant autosomal mutation; a red band tells us of a mutation in the 
father’s gene. In the second key we see the inheritance of a recessive 
autosomal mutation; the red band represents a recessive mutation 
in a father’s gene and in the same gene belonging to the mother; in 
the dominant form, only one copy is necessary for the individual to 
be affected, and in the recessive form, both copies of the same gene 
must be altered. (Modified from REHM, 2003)
Non-syndromic HL
One single gene, GJB2 (Gap Junction β2), explains 
more than 50% of recessive hearing loss cases. Connexin 
26 (Cx26), a protein coded by GJB2, belongs to a family 
of gap-junction proteins which are responsible for the 
transport of ions, metabolites and secondary messengers2. 
Animal studies suggest that the Cx26 participates in the 
recycling of potassium ions back to the cochlear duct 
endolymph, after stimulation by sensorial hair cells2. This 
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non-syndromic recessive autosomal hearing loss in the 
DFNB1 locus of chromosome 13q11-12, is characterized for 
being congenital, typically non-progressive and moderate 
to profound3. The locus has two genes, GJB2 e GJB63,6,7.
-The POU3F4 codifies a transcription factor. The 
HL is X-linked, non-syndromic, progressive and profound 
(DFN3) and may have a conductive component due to 
footplate fixation. CT scan can be useful; an enlargement 
in the internal acoustic meatus or dilation between the 
internal acoustic meatus and the inner ear may be seen. 
The perilymphatic pressure is increased and the inner 
ear perilymph may pour during the surgical removal of 
the stapes3.
Syndromic HLs
Pendred’s syndrome: is responsible for 4 to 10% of 
the hereditary pre-speech hearing loss in the world3,4. One 
of the most common forms of syndromic HL is a recessive 
autosomal disorder made up of HL and a defect in the 
organification of the thyroid hormone, thus forming an 
euthyroidism goiter. The goiter is not consistently present 
and sometimes is manifested only in adults3. An enlarge-
ment in the vestibular aqueduct was found in almost all 
the patients and is associated with a dysmorphic cochlea, 
which has 1.5 and not 2.5 turns (Mondini’s dysplasia)3,4. 
The HL is characteristically pre-speech (not necessarily 
congenital), sensorineural or rarely mixed, from severe to 
profound, frequently stable; however it may be fluctuating 
and progressive3,4. Mutations in the SLC26A4 gene, also 
known as PDS, respond for the majority, if not for all the 
cases of Pendred’s syndrome. A useful laboratorial test for 
the diagnosis is the test of perchlorate discharge, and we 
may also use CT scan38,9.
Usher’s syndrome: recessive autosomal disorder, 
characterized by HL, progressive eyesight loss because 
of retinitis pigmentaris and, in some cases, balance disor-
ders. The syndrome is genetically heterogeneous. There 
are different genes that may cause the syndrome. It is 
clinically divided in: type 1, type 2, type 3 and atypical. 
The type 1 Usher’s syndrome is characterized by severe to 
profound congenital HL, retinitis pigmentaris that starts in 
the pre-pubertal age, and the lack of vestibular reflexes. 
HL in Usher’s syndrome types 1 and 2 is congenital, while 
retinitis pigmentaris may be of late onset and not noticed 
until adolescence4. Estimated prevalence is of 3 to 4.5 in 
100,00010. The VIIa myosin gene is responsible for type 
1B Usher’s syndrome; the VIIa myosin is expressed in the 
hair cells of the Organ of Corti and in the vestibule; in the 
retina, the VIIa myosin is present in the retina pigmented 
epithelial cells10.
Alport’s syndrome: caused by alterations in the 
type IV collagen chains; and symptoms reflect the basal 
membrane involvement in different organs. The X-linked 
inheritance is predominant in 85% of the cases, and the 
recessive autosomal form is responsible for 15% of the 
cases. It is characterized by hematuria, which evolves to 
renal failure and may be accompanied by SNHL and ocular 
defects. The incidence of Alport’s syndrome is reported 
as being 1 in 200 thousand. The HL is a frequent finding 
and one of the first symptoms of this syndrome, being 
also a relevant prognostic factor in regards of the renal 
involvement. The HL is of variable intensity, progressive, 
bilateral and symmetrical, involving the middle range and 
high frequencies. In investigating SNHL in children with 
hematuria, in adolescents and male adults in end-stage 
renal failure, and in patients with family history of renal 
disease in siblings or relatives in their mothers’ side, one 
must consider the diagnosis of Alport’s syndrome. Becau-
se of its complexity and high costs, the available genetic 
diagnostic tests are restricted to selected cases11-13.
Jervell’s and Lange-Nielsen’s syndrome: mutations 
in KCNQ1 or KCNE1, recessive autosomal inheritance, 
delayed repolarization of the potassium channel, with 
profound SNHL, cochleo-saccular dysplasia (Scheibe), 
abnormal cardiac conduction, prolonged QT interval and 
sudden death. The cardiac problem may pass undiagnosed 
Figure 3. Inheritance mode - this key represents an X-linked recessive 
mutation; the daughters that inherit the altered copy from the mother 
will not be affected, because they receive one normal copy from the 
father, and the sons have a 50% chance of inheriting the altered X 
chromosome from the mother. (Modified from Rehm, 2003)
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and it may prove difficult to detect1,4,14.
Mitochondrial HLs
SNHL is present in 42 to 70% of the individuals 
with mitochondrial disorders and may be syndromic or 
not. Mutations in the mitochondrial DNA were identified 
in approximately 3% of the patients with SNHL, and the 
mutations are transmitted exclusively from the mother3. 
Among the patients who receive conventional treatment 
with aminoglycosides (at therapeutic levels and for a 
short period of time), more than 25% presented SNHL; 
and 50% of them are carriers of the 12S rRNA mutation. 
The genetic mitochondrial HL is based on the high need 
of ATP by the cochlear hair cells, and the reduction in 
available ATP - caused by mitochondrial oxidative phos-
phorylation dysfunction brought about by the mutations, 
results in disorders of the ionic gradient in the inner ear. 
Mitochondrial mutations may be related to age-related 
progressive hearing loss - presbycusis3.
Mitochondrial SNHL may be syndromic. Seen in 
the Kearns-Sayre syndrome (progressive ophthalmoplegia 
and HL); in the mitochondrial encephalopathy with lactic 
acidosis and stroke episodes (MELAS) or, in diabetes and 
maternal inheritance HL3.
Genetic Hearing Loss Assessment
As soon as one suspects of genetic SNHL, a com-
plete pre-natal, medical and family history should be 
collected. The clinical and genetic exams are necessary in 
order to rule out characteristics which are common to the 
syndromic or congenital infectious etiology. An ophthal-
mology exam must be carried out, since ocular alterations 
are present in more than half the children with HL from 
severe to profound. Lab tests must be individualized 
and directed according to diagnostic suspicion. TSH and 
perchlorate discharge test in the suspicion of Pendred’s 
syndrome; urine test and renal function test in children 
with possible Alport’s syndrome; an EKG to assess the QT 
interval in the Jervell’s and Lange-Nielsen’s syndromes. 
Image studies may include high resolution CT scans in 
order to assess Mondini’s malformation or an MRI to see 
the auditory nerve, rule out aplasia or infectious inner ear 
destruction, being especially important before a cochlear 
implant surgery3. Audiograms are important components 
of the assessment process15. Genetic tests have implications 
to all family members, and the genetic confidentiality of 
the patient’s relatives must be considered15. Family history 
may stigmatize family members, it may be necessary to 
contact family members in order to reach an accurate in-
terpretation of results, always respecting patients’ privacy 
and autonomy.
The array of molecular tests clinically available or 




Detailed family history is one of the most important 
clues as to the HL etiology, defining the inheritance pattern 
in the family. It is important to collect details on the gene-
ral health and hearing of siblings, parents, grandparents 
and other close relatives. It is also relevant to check for 
consanguinity and family ethnic background. A careful 
physical exam may identify characteristics of syndromes 
or confirm an isolated case (non-syndromic). 
As we mentioned before, the laboratorial tests must 
be confirmed according to clinical suspicion. The audio-
grams are important to determine the degree of hearing 
loss, in order to follow the HL in evolutional cases and also 
to guide patient rehabilitation. It is important to compare 
the patient’s audiologic results with those of other family 
members.  
The assessment of a patient with HL requires a multi-
disciplinary approach and must include advice and support 
to the parents, and genetic counseling aims at optimizing 
the use of the most adequate clinical resources. 
Family genetic evaluation is also paramount in the 
diagnostic process and that of ordering specific genetic 
tests in a child with hearing impairment. Parents should be 
informed on the HL cause and behavior, whether or not it 
impacts other organs and the possibility of it affecting other 
children in the family or family members. Genetic tests are 
integral part of the assessment in an attempt to confirm the 
specific diagnosis. Parents must be informed on the diag-
nosis and conditions that follow the clinical manifestation, 
prognosis, inheritance mode and treatment options. If the 
genetic tests result in important health consequences for 
the health of relatives, they must be contacted. Pre and 
post testing genetic counseling is important for the patient 
to understand the advantages and limitations of a particular 
genetic test, as well as the resulting consequences for the 
patient and his family. 
Genetic tests are part of the assessment and must 
help to confirm or rule out a specific diagnosis. The fast 
introduction of genetic tests in the clinical practice makes 
it necessary to search for information on the risks and 
benefits of such tests and also to what extent the exam 
introduction is useful and appropriate. GJB2 (connexin 26) 
is the most common cause of non-syndromic HL, therefore, 
it must the first step in mutation analysis investigation, after 
obtaining a signed informed consent. Peripheral blood 
and mouth mucosa cells collected with a swab may be 
analyzed. The methods employed in order to identify a 
GJB2 mutation are fast, relatively inexpensive, highly sensi-
tive and specific, but limited, since the number of mutation 
points investigated is low. It may be useful in individuals 
with genetic hearing loss, of unknown etiology, without 
other clear clues and negative image studies (Figure 4).
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The diagnosis of SNHL, led by genetics and bio-
markers will certainly progress in the next 10 years; early 
diagnosis, guided therapy and disease monitoring will 
replace the current late diagnosis and therapy paradigm11 
(Figure 5).
Figure 4. Genetic SNHL screening - The otorhinolaryngologist must 
have a high degree of suspicion in order to determine the syndromic 
forms (evidences of syncope or sudden death in other family mem-
bers, in the syndromes of Jervell and Lange-Nielsen; enlargement of 
the vestibular aqueduct and positive perchlorate discharge test in the 
Pendred’s syndrome); the tests ordered must be guided by clinical 
suspicion; in more than 50% of the children with SNHL severe to pro-
found, there are ophthalmologic alterations. When the SNHL happens 
alone and the image exams are negative, the Connexin 26 test should 
be proposed, respecting the patient’s autonomy and privacy. AR: reces-
sive autosomal; AD: dominant autosomal; LX: X-linked; Mitochondrial: 
mitochondrial inheritance.
Figure 5. SNHL diagnosis - SNHL diagnosis will be driven by genetics 
and biomarkers. (Modified from Bell, 2004)
CONCLUSION
-Epidemiological data estimate that at least 50% 
of the pre-speech hearing losses are caused by genetic 
alterations.
-Clinical and family histories are extremely impor-
tant in genetic SNHL diagnosis and contribute to determine 
inheritance patterns. 
-Through high suspicion indexes, syndromic causes 
may be diagnosed or ruled out with careful evaluation, 
and the HL molecular basis may be better determined 
then before. 
-Genetic tests and mitochondrial inheritance must 
be considered in families with multiple individuals affec-
ted, and the latter is ruled out if there is clear transmission 
from a man.
-In non-syndromic SNHLs, GJB2 mutation analysis 
must be proposed.
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